These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

371 related items for PubMed ID: 22363436

  • 1. Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC): new insights on the role of phosphatydil-inositol-3 kinase.
    Scrima M, De Marco C, Fabiani F, Franco R, Pirozzi G, Rocco G, Ravo M, Weisz A, Zoppoli P, Ceccarelli M, Botti G, Malanga D, Viglietto G.
    PLoS One; 2012; 7(2):e30427. PubMed ID: 22363436
    [Abstract] [Full Text] [Related]

  • 2. Specific gene expression signatures induced by the multiple oncogenic alterations that occur within the PTEN/PI3K/AKT pathway in lung cancer.
    De Marco C, Laudanna C, Rinaldo N, Oliveira DM, Ravo M, Weisz A, Ceccarelli M, Caira E, Rizzuto A, Zoppoli P, Malanga D, Viglietto G.
    PLoS One; 2017; 12(6):e0178865. PubMed ID: 28662101
    [Abstract] [Full Text] [Related]

  • 3. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
    Trigka EA, Levidou G, Saetta AA, Chatziandreou I, Tomos P, Thalassinos N, Anastasiou N, Spartalis E, Kavantzas N, Patsouris E, Korkolopoulou P.
    Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
    [Abstract] [Full Text] [Related]

  • 4. Analysis of miRNA profiles identified miR-196a as a crucial mediator of aberrant PI3K/AKT signaling in lung cancer cells.
    Guerriero I, D'Angelo D, Pallante P, Santos M, Scrima M, Malanga D, De Marco C, Ravo M, Weisz A, Laudanna C, Ceccarelli M, Falco G, Rizzuto A, Viglietto G.
    Oncotarget; 2017 Mar 21; 8(12):19172-19191. PubMed ID: 27880728
    [Abstract] [Full Text] [Related]

  • 5. Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia.
    Yip WK, Choo CW, Leong VC, Leong PP, Jabar MF, Seow HF.
    APMIS; 2013 Oct 21; 121(10):954-66. PubMed ID: 23992303
    [Abstract] [Full Text] [Related]

  • 6. Multiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinoma.
    De Marco C, Rinaldo N, Bruni P, Malzoni C, Zullo F, Fabiani F, Losito S, Scrima M, Marino FZ, Franco R, Quintiero A, Agosti V, Viglietto G.
    PLoS One; 2013 Oct 21; 8(2):e55362. PubMed ID: 23408974
    [Abstract] [Full Text] [Related]

  • 7. Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells.
    Chen J, Bi H, Hou J, Zhang X, Zhang C, Yue L, Wen X, Liu D, Shi H, Yuan J, Liu J, Liu B.
    Cell Death Dis; 2013 Sep 26; 4(9):e814. PubMed ID: 24071646
    [Abstract] [Full Text] [Related]

  • 8. Diverse prognostic roles of Akt isoforms, PTEN and PI3K in tumor epithelial cells and stromal compartment in non-small cell lung cancer.
    Al-Saad S, Donnem T, Al-Shibli K, Persson M, Bremnes RM, Busund LT.
    Anticancer Res; 2009 Oct 26; 29(10):4175-83. PubMed ID: 19846969
    [Abstract] [Full Text] [Related]

  • 9. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis.
    Lu C, Shan Z, Hong J, Yang L.
    Int J Oncol; 2017 Jul 26; 51(1):235-244. PubMed ID: 28534966
    [Abstract] [Full Text] [Related]

  • 10. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.
    Lee SY, Kim MJ, Jin G, Yoo SS, Park JY, Choi JE, Jeon HS, Cho S, Lee EB, Cha SI, Park TI, Kim CH, Jung TH, Park JY.
    J Thorac Oncol; 2010 Nov 26; 5(11):1734-40. PubMed ID: 20881644
    [Abstract] [Full Text] [Related]

  • 11. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
    Yuen HF, Chan KK, Grills C, Murray JT, Platt-Higgins A, Eldin OS, O'Byrne K, Janne P, Fennell DA, Johnston PG, Rudland PS, El-Tanani M.
    Clin Cancer Res; 2012 Jan 15; 18(2):380-91. PubMed ID: 22090358
    [Abstract] [Full Text] [Related]

  • 12. MiR-4299 suppresses non-small cell lung cancer cell proliferation, migration and invasion through modulating PTEN/AKT/PI3K pathway.
    Yang WB, Zhang WP, Shi JL, Wang JW.
    Eur Rev Med Pharmacol Sci; 2018 Jun 15; 22(11):3408-3414. PubMed ID: 29917192
    [Abstract] [Full Text] [Related]

  • 13. MicroRNA-4286 promotes cell proliferation, migration, and invasion via PTEN regulation of the PI3K/Akt pathway in non-small cell lung cancer.
    Ling C, Wang X, Zhu J, Tang H, Du W, Zeng Y, Sun L, Huang JA, Liu Z.
    Cancer Med; 2019 Jul 15; 8(7):3520-3531. PubMed ID: 31074594
    [Abstract] [Full Text] [Related]

  • 14. PI3K/AKT pathway activation in bladder carcinogenesis.
    Calderaro J, Rebouissou S, de Koning L, Masmoudi A, Hérault A, Dubois T, Maille P, Soyeux P, Sibony M, de la Taille A, Vordos D, Lebret T, Radvanyi F, Allory Y.
    Int J Cancer; 2014 Apr 15; 134(8):1776-84. PubMed ID: 24122582
    [Abstract] [Full Text] [Related]

  • 15. Ubiquitin specific peptidase 49 inhibits non-small cell lung cancer cell growth by suppressing PI3K/AKT signaling.
    Shen WM, Yin JN, Xu RJ, Xu DF, Zheng SY.
    Kaohsiung J Med Sci; 2019 Jul 15; 35(7):401-407. PubMed ID: 31001918
    [Abstract] [Full Text] [Related]

  • 16. Highly expressed long non-coding RNA CRNDE promotes cell proliferation through PI3K/AKT signalling in non-small cell lung carcinoma.
    Liu XX, Xiong HP, Huang JS, Qi K, Xu JJ.
    Clin Exp Pharmacol Physiol; 2017 Aug 15; 44(8):895-902. PubMed ID: 28477368
    [Abstract] [Full Text] [Related]

  • 17. Effect of microRNA-135a on Cell Proliferation, Migration, Invasion, Apoptosis and Tumor Angiogenesis Through the IGF-1/PI3K/Akt Signaling Pathway in Non-Small Cell Lung Cancer.
    Zhou Y, Li S, Li J, Wang D, Li Q.
    Cell Physiol Biochem; 2017 Aug 15; 42(4):1431-1446. PubMed ID: 28715819
    [Abstract] [Full Text] [Related]

  • 18. MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells.
    Kharbanda A, Rajabi H, Jin C, Alam M, Wong KK, Kufe D.
    Oncotarget; 2014 Oct 15; 5(19):8893-905. PubMed ID: 25245423
    [Abstract] [Full Text] [Related]

  • 19. Dual roles of miR-374a by modulated c-Jun respectively targets CCND1-inducing PI3K/AKT signal and PTEN-suppressing Wnt/β-catenin signaling in non-small-cell lung cancer.
    Zhao M, Xu P, Liu Z, Zhen Y, Chen Y, Liu Y, Fu Q, Deng X, Liang Z, Li Y, Lin X, Fang W.
    Cell Death Dis; 2018 Jan 23; 9(2):78. PubMed ID: 29362431
    [Abstract] [Full Text] [Related]

  • 20. PIK3CA alterations in Middle Eastern ovarian cancers.
    Abubaker J, Bavi P, Al-Haqawi W, Jehan Z, Munkarah A, Uddin S, Al-Kuraya KS.
    Mol Cancer; 2009 Jul 28; 8():51. PubMed ID: 19638206
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.